CAS Insight

molecules of the month

bradanicline (ATA-101 or TC-5619)

alpha-7 nicotinic receptor agonist

Ph. II candidate for chronic cough

drug repurposing

J Pharmacol Exp Ther

Johns Hopkins

alpha-7 nicotinic receptor agonist - Johns Hopkins
1 min read

bradanicline (ATA-101 or TC-5619) is a molecule first disclosed a decade ago by Targacept. It is a selective agonist of the alpha-7 neuronal nicotinic acetylcholine receptor, and was intended as a drug candidate for treatment of cognitive impairment in neurological disorders. It is highly selective for the CNS over peripheral receptor subtypes. Interestingly, in this article, the authors show that the molecule dose-dependently inhibits coughing in guinea pigs. Nicotine has been demonstrated to have anti-tussive properties, and it is suggested that this nicotinic receptor subtype is responsible for that effect.In humans, ATA-101 was well-tolerated in several clinical studies when given daily for several weeks at doses as high as 125 mg QD, and entered Ph. II to evaluate efficacy in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: